Reported about 12 hours ago
Johnson & Johnson's stock fell to around $143 per share despite surpassing Wall Street's expectations with $88.8 billion in total sales and $5.79 in earnings per share for 2024. The decline is attributed to concerns over ongoing talc lawsuits, potential foreign exchange impacts, and competition faced by its drugs as generics enter the market. Additionally, J&J announced its acquisition of Intra-Cellular for $14.6 billion, primarily funded through debt, as part of a continued strategy to bolster its pharmaceutical and medical device portfolio.
Source: YAHOO